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Abstract
Objective Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are rare small to medium-size
vessel systemic diseases. As their clinical picture, organ involvement, and factors influencing outcome may differ
between countries and geographical areas, we decided to describe a large cohort of Polish AAV patients coming from
several referral centers—members of the Scientific Consortium of the Polish Vasculitis Registry (POLVAS).
Methods We conducted a systematic multicenter retrospective study of adult patients diagnosed with AAV between
Jan 1990 and Dec 2016 to analyze their clinical picture, organ involvement, and factors influencing outcome. Patients
were enrolled to the study by nine centers (14 clinical wards) from seven Voivodeships populated by 22.3 mln inhab-
itants (58.2% of the Polish population).
Results Participating centers included 625 AAV patients into the registry. Their distribution was as follows: 417 patients
(66.7%) with GPA, 106 (17.0%) with MPA, and 102 (16.3%) with EGPA. Male-to-female ratios were almost 1:1 for
GPA (210/207) and MPA (54/52), but EGPA was twice more frequent among women (34/68). Clinical manifestations
and organ involvement were analyzed by clinical phenotype. Their clinical manifestations seem very similar to other
European countries, but interestingly, men with GPA appeared to follow a more severe course than the women. Fifty five
patients died. In GPA, two variables were significantly associated with death: permanent renal replacement therapy
(PRRT) and respiratory involvement (univariate analysis). In multivariate analysis, PRRT (OR = 5.3; 95% confidence
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interval (CI) = 2.3–12.2), respiratory involvement (OR = 3.2; 95% CI = 1.06–9.7), and, in addition, age > 65 (OR = 2.6;
95% CI = 1.05–6.6) were independently associated with death. In MPA, also three variables were observed to be
independent predictors of death: PRRT (OR = 5.7; 95% CI = 1.3–25.5), skin involvement (OR = 4.4; 95% CI = 1.02–
19.6), and age > 65 (OR = 6.3; 95% CI = 1.18–33.7).
Conclusions In this first multicenter retrospective study of the Polish AAV patients, we have shown that their demographic
characteristics, disease manifestations, and predictors of fatal outcome follow the same pattern as those from other European
countries, with men possibly suffering from more severe course of the disease.
Keywords Antineutrophil cytoplasmic antibodies . Churg-Strauss syndrome . Microscopic polyangiitis . Registries . Wegener’s
granulomatosis
Introduction
Vascultides are a heterogeneous group of rare diseases
with unknown etiology and the clinical spectrum ranging
from life-threatening systemic disease, through single or-
gan involvement to minor isolated skin changes [1, 2].
Present nomenclature and definitions of systemic vascu-
litides have been proposed in 2012 at the International
Chapel Hill Consensus Conference (CHCC 2012) [3].
Among var ious forms of vascul i t ic syndromes
(antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitides (AAV)), belong to the small to medium-size
vessel systemic diseases comprising granulomatosis with
polyangiitis (GPA, previously known as Wegener’s gran-
ulomatosis (WG), microscopic polyangiitis (MPA), and
eosinophilic granulomatosis with polyangiitis (EGPA,
previously known as Churg-Strauss syndrome (CSS)).
Despite progress made in the management of AAV, those
patients still remain at an increased risk of death. Recent
publication indicates that standardized mortality ratio in
AAV patients is 2.7-fold higher compared with the gen-
eral population [4].
Epidemiology and clinical characteristics of AAV have
been described in several studies, most often, however,
analyzing jointly GPA and MPA [5, 6] and considering
both entities as a spectrum of the same pathological pro-
cess. EGPA patients were usually analyzed separately [5,
7]. However, ANCA specificity, clinical phenotype, and
outcome of AAV patients may differ depending on geo-
graphic area and ethnicity [8–10].
For this reason, we decided to study in a retrospective
manner immunologic profile, clinical picture, and the
disease outcome in ethically uniform Polish AAV pa-
tients depending on their phenotype. We also attempted
to identify in these patients poor outcome predictors. As
studies on Polish AAV patients were usually limited to
one center, including single diagnosis and relatively
small number of patients [11, 12], we established
Scientific Consortium of the Polish Vasculitis Registry
(POLVAS) [13–15] to increase substantially the number
of analyzed subjects.
Methods
We conducted a multicenter retrospective study of all adult
patients diagnosed with AAV by participating centers between
1990 and 2016. Their clinical and laboratory data were col-
lected in POLVAS registry [13] by nine referral centers (14
clinical wards) from seven Voivodeships with 22.3 mln inhab-
itants, encompassing 58.2% of the Polish population.
Specialties of the centers included rheumatology (10), ne-
phrology (2), metabolic diseases (1), and clinical immunology
(1). The work described in this article has been carried out in
accordance with The Code of Ethics of the World Medical
Association (Declaration of Helsinki) for experiments involv-
ing humans; the locally appointed ethics committee of each
partner has approved the research protocol, and informed con-
sent has been obtained from the subjects (or their legally au-
thorized representative). Study protocol was approved by
Bioethical Commission of Jagiellonian University, decision
No 122.6120.25.2016. Only patients who met the American
College of Rheumatology (ACR) classification criteria for
GPA(WG) or EGPA(CSS) and fulfilled requirements for the
nomenclature of GPA, MPA, and EGPA according to CHCC
2012 [3] were included in the study. Specific organ involve-
ment, disease relapse, and disease remission were defined ret-
rospectively according to BVAS v3 [16]. Patients diagnosed
with AAV according to medical documentation but lost to
follow-up at the time of data collection were not included to
the study.
Following data were systematically collected according to
the common protocol: demographics, clinical, laboratory, ra-
diographic, pathology, and treatment details. ANCA positivity
in the earliest patients included into Registry (1990–2000)
was detected by an indirect immunofluorescence (IIF) method
only and identified as cANCA or pANCA positivity. Later,
ANCA positivity was detected by both, ELISA (anti-PR3 or
anti-MPO antibodies) and, if necessary, by IIF.
Statistical analysis
Categorical data were summarized as percentages; signif-
icant differences or associations were analyzed using the
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χ2 test or Fisher’s exact tests. Continuous variables are
presented as mean and/or median and interquartile range
[IQR], depending on normality of data distribution dem-
onstrated by Kolmogorov–Smirnov test. Associations of
quantitative data were analyzed with Student’s t test and
with the nonparametric Mann–Whitney U test or the
Kruskal–Wallis test. For analysis of risks related to mor-
tality and the need for permanent renal replacement ther-
apy (PRRT), variables shown to be statistically significant
in the univariate analysis were further analyzed in a mul-
tivariate logistic regression model. Statistical analysis was
performed using Statistica 13 software.
Results
Demographic analysis of AAV patients
Participating centers included a total of 625 adult AAV pa-
tients into our retrospective registry. All patients were uni-
formly Caucasian. Demographic data of our AAV patients
and basic information about their ANCA status are given in
Table 1. Among 625 patients, only 26 (4.2%) were diagnosed
between 1990 and 2000 with the remaining 599 subjects di-
agnosed after the year 2000.
AAV patients from POLVAS registry included 66.7% di-
agnosed with GPA, 17.0% withMPA, and 16.3%with EGPA.
As in other European countries, male-to-female ratio was al-
most 1:1 for GPA (210/207) and MPA (54/52). Unexpectedly,
EGPA was diagnosed twice more often among women
(Table 1).
Demographic characteristics of AAV patients
according to their ANCA specificity
In our cohort, 127 subjects were identified with anti-MPO+
and 334 with anti-PR3+ (see Suppl. Tab.S1 and S2). Analysis
by antibody specificity did not add important new information
to the one obtained by phenotype analysis. Understandably,
EGPA demographic characteristic significantly differed from
that of MPA—main AAV group with anti-MPO+ antibodies.
Surprisingly, the age at diagnosis in EGPA anti-MPO+ sub-
group and male to female ratio (1:1) was similar to other anti-
MPO+ positive AAV patients (median age at diagnosis
56.9 years vs 63.1 years; p = 0.25) (Suppl. Tab.S1 and S3).
Clinical manifestations of AAV
Organ involvement and laboratory parameters of different
AAV phenotypes are summarized in Table 1. The main organs
affected in GPA and EGPA were respiratory tract and ENT,
whereas in MPA, kidneys followed by lower respiratory tract.
EGPA was the entity characterized by the highest number of
organs involved. Heart and neurological involvement was also
highly represented in this group as compared to GPA and
MPA. In terms of kidney function, the highest (ever docu-
mented) maximal serum creatinine concentration was ob-
served in MPA patients, as was the need for temporary or
permanent RRT.
Interestingly, 2.9% of patients with GPA (10 out of 342 in
whom differential blood count was available) showed in-
creased blood eosinophil count (defined as > 1500 cells/mm3
or > 10% of total leukocyte count).
Disease relapses were not only prevalent in GPA patients
but also affected many EGPA subjects with the shortest time
between diagnosis and the first relapse in the latter. Relapse
rate (expressed as number of relapses per 100 patients/years)
was higher among GPA (18.0) and EGPA (25.2) patients than
in the MPA group (12.0) (Table 1). Of note, in our cohort, the
average observation time in MPA group was significantly
shorter (median 27.4 months) than in GPA (61.9 months)
and EGPA (68 months).
Biopsy was performed in 381 (61%) cases (renal-106,
lung-65, muscle, nerve-1, ENT-115, skin-42, eye-5, muscle-
4, intestine-9, other-31). The diagnosis of vasculitis was sup-
ported by histopathology in 310 (81.4%) subjects.
Factors related to poor outcome
Among all AAV subjects who died during retrospective ob-
servation (n = 55; 8.8%), 42 suffered from GPA and 13 from
MPA, which corresponds to 10.1% and 12.3% of patients,
respectively (Table 2). AAV patients who died showed higher
serum creatinine concentration ever observed, more often re-
quired permanent RRT, and suffered from multiorgan disease
(Table 2).
The age of GPA patients who died did not differ from those
who remained alive, but it appears that there were slightly
more men (26 men vs 16 women), although this difference
did not reach statistical significance. GPA patients who died
showed more frequently respiratory and kidney involvement
and were more prone to relapse, while MPA patients were
older, and showed higher rate of skin and ENT involvement
(Table 2).
Analysis of factors related to death in AAV identified var-
ious aspects of kidney involvement as a key health issue in
both GPA and MPA. This prompted us to investigate which
factors differentiated between patients requiring temporary or
permanent renal replacement therapy from those who did not
(Table 3).
In general, MPA patients significantly more often required
RRT than the GPA ones (44% vs 21%; p < 0.0001). GPA
patients who were never dialyzed (330; 79%) were on average
7 years younger (47.6 years vs 54.3 years p < 0.001) and
showed ENT involvement significantly more frequently than
those dialyzed. Again, men prevailed among GPA patients
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requiring dialysis (M/F, 53/34; p < 0.05). Dialyzed GPA pa-
tients also showed significantly higher serum CRP concentra-
tion at baseline (median 54 mg/l vs 32 mg/l; p < 0.05).
In the subgroup of MPA patients defined by dialysis status,
no differences in their demographic characteristics were
observed. The only clinical difference was GI tract involve-
ment which was more common in dialyzed patients (19.1% vs
5.1%, p < 0.05) (Table 3).
Patients who died, both in GPA and MPA group experi-
enced disease relapses more often. For this reason, we decided
Table 1 Demographic, clinical characteristics, and ANCA status of AAV patients in the POLVAS Registry






No. of patients 417 106 102 p
Male/female 210/207 54/52 34/68 NS < 0.01 < 0.05
Age (years); median, [range] 51.4 [13–80] 63.7 [19–85] 44.5 [9–85] < 0.01 < 0.05 < 0.0001
ANCA positive1; n (%) 376 (93.3) 104 (98.1) 43 (47.8) NS < 0.00001 < 0.00001
ANCA negative; n (%) 26 (6.7) 2 (1.9) 47 (52.2)
ANCA–missing data/not performed 15 0 12
cANCA/anti-PR32 344 (85.6) 9 (8.5) 10 (11.1) < 0.00001 < 0.00001 < 0.00001
pANCA/anti-MPO3 19 (4.7) 87 (82.1) 28 (31.1)
Double positive2 13 (3.2) 6 (5.7) 2 (2.2)
Time to diagnosis4 (month); median, [IQR] 5.95 [2.95–14.0] 5.01 [2–10.95] 14.9 [7.7–34.8] NS < 0.001 < 0.0001
Organ involvement
General n (%) 355 (85.1) 83 (78.3) 87 (85.3) NS NS NS
Skin n (%) 140 (33.6) 24 (22.6) 51 (50) < 0.05 < 0.01 < 0.001
Eye n (%) 114 (27.3) 4 (3.8) 6 (5.9) < 0.0001 < 0.0001 NS
ENT n (%) 315 (75.5) 18 (17.0) 82 (80.4) < 0.0001 NS < 0.0001
Respiratory n (%) 315 (75.5) 60 (56.6) 100 (98.0) < 0.0001 < 0.0001 < 0.0001
Heart n (%) 55 (13.2) 11 (10.4) 43 (42.2) NS < 0.0001 <0.0001
GI n (%) 46 (11.0) 12 (11.3) 25 (24.5) NS < 0.001 < 0.05
Renal n (%) 252 (60.4) 101 (95.3) 25 (24.5) < 0.0001 < 0.0001 < 0.0001
Urinary n (%) 8 (1.9) 3 (2.8) 0 NS NS NS
CNS n (%) 45(10.8) 2 (1.9) 8 (7.8) < 0.01 NS < 0.05
Neurological n (%) 75 (18.0) 20 (18.9) 50 (49.0) NS < 0.0001 < 0.0001
Creatinine max5 (mg/dl); median, [IQR] 1.04 [1.0–3.0] 3.8 [2.0–6.0] 0.84 [0.7–1.0] < 0.0001 < 0.0001 < 0.0001
Number of organs involved; mean (median),
[IQR]
3.27 (3) [2–4] 2.4 (2) [2–3] 3.82 (4) [3–5] < 0.0001 < 0.01 < 0.0001







< 0.0001 NS < 0.0001
Patients with relapse n (%) 243 (58.3) 27 (25.5) 70 (68.6) < 0.00001 NS < 0.00001
Relapse rate& 18.0 ± 0.8 12.0 ± 1.9 25.2 ± 1.9 < 0.05 < 0.05 < 0.01
Time to relapse6 (month); median, [IQR] 16 [8–31] 17 [9–45] 11 [4.5–19] NS < 0.001 < 0.05
CTX median7 (g); [IQR] 9 [5.35–16] 5 [2–7] 6 [5.7–8.36] < 0.0001 NS NS
Permanent renal replacement therapy n (%) 55 (13.2) 36 (34) 0 < 0.0001 < 0.0001 < 0.0001
Temporary renal replacement therapy n (%) 32(7.7) 11 (10.4) 0 NS < 0.01 < 0.001
&Relapse rate = number of relapses per 100 patients per 1 year
1 Positive by either IIF or ELISA, or both
2 Positive for either cANCA by IIF or anti-PR3 by ELISA, or both
3 Positive for either pANCA by IIF or anti-MPO by ELISA, or both
4 Time from reported onset of symptoms to diagnosis
5 Creatinine max-maximum creatinine concentration ever
6 Time to relapse = time in months between diagnosis and the first disease relapse
7 Cumulative dose of cyclophosphamide (CTX)
ENT, ear, nose, throat; CNS, central nervous system; GI, gastrointestinal tract; IQR, interquartile range, CTX, cyclophosphamide
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to analyze further possible factors influencing relapse rate
(Suppl. Tab. S4).
In the GPA group (during an average observation time of
49.1 months), 175 patients (42%) never experienced a relapse,
while 58% experienced at least one relapse (average observa-
tion time 96.7 months). In MPA patients, only 27 patients
(34%) relapsed (average observation time in relapsing
group—64.2 months). Observation time in both subgroups
differed, but after adjustment for the duration of the disease,
their relapse rate was very similar (Suppl. Tab. S4).
Relapsing GPA patients were younger than the subgroup
without any relapse. They also showed increased ENTand eye
involvement (81% vs 68%; p < 0.01 and 31.8% vs 21.1%;
p < 0.01) and low rate of GI tract involvement (5.8% vs
14.1%; p < 0.01).
Relapsing MPA subgroup did not differ by age from the
non-relapsing ones. Clinical differences between these groups
resembled, although less significantly, GPA subjects.
As we observed, an increased participation of men among
those GPA patients who died and those requiring RRT
(Table 2 and Suppl. Tab. S4), we decided to see into possible
differences in the disease course and organ involvement be-
tween male and female AAV subjects.
Table 2 Factors related to death in AAV patients
GPA MPA
Death cases Alive patients Death cases Alive patients
No. of patients 42 375 13 93
Age (years); median 55.5 51.1 71.1 62.9+
Male/female 26/16 184/191 6/7 48/45
Time to diagnosis1 (month); median, [IQR] 6.0 [4.0–14] 5.9 [3.0–13.9] 4.0 [1.8–7.4] 5.3 [2.0–12.0]
Diagnosis to 1. Relapse (month); median, [IQR] 12 [7.8–24] 18 [8.5–33.5] 26.5 [14.25–39] n = 5 17 [9–45]
Average observation time (month) 66.2 72.6+ 20.55 36.2
Number of organs involved; mean (median), [IQR] 3.73 (4) [3–4] 3.22 (3) [2–4]* 3.15 (3) [2–4] 2.3 (2) [2–3]*
Permanent renal replacement therapy; n (%) 15 (35.7) 40 (10.7)# 8 (61.5) 28 (30.1)#
Temporary renal replacement therapy; n (%) 4 (9.5) 28 (7.5) 1 (7.7) 10 (10.7)
Patients with at least one relapse; n (%) 28 (66.7) 214 (57.1)# 5 (38.4) 22 (23.7)#
Relapse rate& 26.4 ± 3.4 19.2 ± 1.0 26.4 ± 10.8 12.0 ± 2.4
Organ involvement
General; n (%) 37 (88.1) 318 (84.8) 12 (92.3) 71 (76.3)
Skin; n (%) 17 (40.5) 123 (32.8) 6 (46.1) 18 (19.3)*
Eye; n (%) 7 (16.7) 107 (28.5) 0 (0) 4 (4.3)
ENT; n (%) 31 (73.8) 284 (75.7) 5 (38.4) 13 (13.9)*
Respiratory; n (%) 38 (90.5) 277 (73.9)* 9 (69.2) 51 (54.8)
Heart; n (%) 8 (19.1) 47 (12.5) 0 (0) 11 (11.8)
GI; n (%) 6 (14.3) 40 (10.7) 3(23.1) 9 (9.7)
Renal; n (%) 32 (76.2) 220 (58.7)* 12 (92.3) 89 (95.6)
Urinary; n (%) 1 (2.4) 7 (1.7) 0 3 (3.2)
CNS; n (%) 6 (14.3) 39 (10.4) 2 (15.4) 0 (0)
Peripheral nerves; n (%) 11 (26.1) 64 (17.1) 4 (30.8) 16 (17.2)
Creatinine max2; (mg/dl); median [IQR] 3 [1.0–6.7] 1.03 [1.0–2.8]* 5 [4.0–6.2] 3 [2.0–6.0]+
CRP at baseline (mg/l); median, [IQR] 64 [22.5–130] 33.2 [8.9–92.8] 49 [33.3–116.5] 30.5 [13.0–81.0]
CTX (g)3; median, [IQR] 7.1 [3.0–13.5] 9 [6–16.2] 1.5 [1.0–3.25] 5.1 [2.4–8.0]+
Smoker/previous smoker/no/missing (n)4 3/7/10/22 22/65/173/92 0/1/5/7 5/36/34/17
*p < 0.05; + p < 0.01; # p < 0.001
&Relapse rate = number of relapses per 100 patient per 1 year
1 Time from reported onset of symptoms to diagnosis
2Maximal serum creatinine concentration ever. Values after initiation of renal replacement therapy are excluded
3 Cumulative dose of cyclophosphamide (CTX)
4 Statistical analysis compared smokers and previous smokers vs no (subjects who never smoked)
ENT, ear, nose, throat; CNS, central nervous system; GI, gastrointestinal tract, IQR, interquartile range, CTX, cyclophosphamide, numbers in italic -
significant statistical difference between groups
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Surprisingly, in the GPA group, male patients compared to
women showed significantly more often respiratory (81.4% vs
69.6%; p < 0.01) and renal (70.9% vs 49.8%; p < 0.00001)
involvement, but suffered from ENT symptoms slightly less
frequently (71.4% vs 79.7%; p < 0.05). Higher rate of renal
and lung involvement in men may have facilitated final diag-
nosis exemplified by a significantly shorter time to diagnosis
in male GPA patients (median 4.9 months vs 7.0 months;
p < 0.01; see Tab.4). In contrast, men and women in the
MPA (Table 4) and EGPA (data not shown) groups showed
only single, isolated differences.
To identify factors independently related to death and the
requirement for PRRT in AAV patients, we additionally per-
formed logistic regression analysis (Table 5). For analysis, we
have chosen parameters significantly different between
groups (death vs alive; any RRT vs no RRT) in previous
analyses (p < 0.05). Analysis included whole AAV group
(here specificity of ANCA antibodies was also added), GPA,
and MPA. EGPA group was not included as there was only
one death among EGPA patients, and no need for renal re-
placement therapy was reported. In the whole AAV group,
independent risk factors for death in univariate analysis were
PRRT, kidney involvement, age > 65 years, and the presence
of c/PR3 ANCA, while in multivariate analysis, it included
PRRT, respiratory involvement, age > 65 years, and the pres-
ence of c/PR3 ANCA. As PRRT risk factors univariate anal-
ysis identified: relapsing disease, age > 65, p/MPO ANCA,
and ENT involvement as a factor negatively associated with
PRRT, whereas multivariate analysis confirmed only a role of
ENT involvement and the presence of p/MPO ANCA, and
added as a significant, although weak risk factor, the presence
of c/PR3 ANCA.
In GPA patients, univariate analysis identified the fol-
lowing risk factors related to death: PRRT and lower
Table 3 Factors related to renal replacement therapy in AAV patients
GPA MPA
No RRT Any RRT No RRT Any RRT
No. of patients 330 87 59 47
Age (years); median 50.1 56.5# 60.5 64.7
Male/female 157/173 53/34* 32/27 22/25
Time to diagnosis1 (month); median [IQR] 6.0 [3.0–14.1] 4.95 [2.0–10] 3.9 [2.0–13.6] 5.8 [2–10.5]
Diagnosis to 1. Relapse (month); median, [IQR] 17.5 [8–30] 15 [10–33] 27 [13–48] 17 [7.5–28]
Average observation time (month) 75.1 82.8 39.9 31.7
Number of organs involved; mean (median) [IQR] 3.25 (3) [2–4] 3.35 (3) [2–4] 2.37 (2) [2, 3] 2.44 (2) [2, 3]
Permanent renal replacement therapy n (%) NA 55 (63.2) NA 36 (76.6)
Temporary renal replacement therapy n (%) NA 32 (36.8) NA 11 (23.4)
Death; n (%) 23 (7.0) 19 (21.8)# 4 (6.8) 9 (19.1)
Patients with relapse n (%) 196 (59.4) 46 (52.9) 15 (25.4) 12 (25.5)
Relapse rate& 19.2 ± 1.0 15.0 ± 1.6 10.8 ± 2.4 14.4 ± 4.8
Organ involvement
General n (%) 274 (83.0) 81 (93.1) 45 (76.3) 38 (80.8)
Skin n (%) 112 (33.9) 28 (32.2) 16 (27.1) 8 (17)
Eye n (%) 100 (30.3) 14(16.1) 4 (6.8) 0 (0)
ENT n (%) 271 (82.1) 44 (50.6)# 9 (15.3) 9 (19.1)
Respiratory n (%) 245 (74.2) 70(80.5) 33 (55.9) 27 (57.5)
Heart n (%) 43 (13.0) 12(13.8) 4 (6.8) 7 (14.9)
GI n (%) 32 (9.7) 14 (16.1) 3 (5.1) 9 (19.1)*
Renal n (%) 165 (50) 87 (100) 55 (93.2) 47 (100)
Urinary n (%) 5 (1.5) 3(3.4) 2 (3.4) 1(2.1)
CNS n (%) 37 (11.2) 8 (9.2) 0 (0) 2 (4.2)
Peripheral nerves n (%) 64 (19.4) 11 (12.6) 14 (23.7) 6 (12.8)
Creatinine max2; (mg/dl); median, [IQR] 1 [1.0–1.7] 6.0 [4.5–8.1]# 2.07 [1.2–3.0] 6.1 [5.0–7.75]#
CRP at baseline (mg/l); median, [IQR] 32 [8.7–88.7] 54 [18–138]* 30 [16–76.6] 34.8 [11.1–103.5]
CTX (g)3; median, [IQR] 9 [6–17] 7.2 [4–15] 6.3 [3.5–9.6] 2.4 [1.3–5.0]#
Smoker/previous smoker/no/missing (n)4 19/52/160/77 6/20/23/36+ 4/18/25/11 1/19/14/13
See Table 2 for legend
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respiratory tract involvement. Multivariate analyses
added elder age at diagnosis (> 65 years). Analysis of
risk factors for PRRT identified ENT involvement as a
factor negatively associated with risk of dialysis by both
univariate and multivariate analysis. In addition, multi-
variate analyses identified multiorgan disease as directly
and independently related to PRRT (p < 0.01).
InMPA patients, factors related to death by univariate anal-
ysis include PRRT, skin and ENT involvement, and the age >
65 years at diagnosis. Multivariate logistic regression analyses
confirmed significance of all three factors. In the MPA group,
among factors analyzed, none was identified by regression
analysis as related to PRRT.
Discussion
POLVAS registry is the first large database of AAV patients in
Poland. Data were obtained from tertiary reference centers
representing several specialties to cover a spectrum of differ-
ent possible symptomatology at presentation and during the
course of the disease [17]. In general, major demographic
characteristics and patterns of organ involvement in our eth-
nically homogenous Caucasian population were consistent
with already published major AAV series from the UK,
French, and Spanish cohorts [8, 9], [18–20]. Frequency of
AAV was also typical for other European countries. Male to
female ratio was 1:1 for GPA and MPA, and 1:2 in for EGPA.
Table 4 Demographic characteristics and comparison of organ involvement and laboratory parameters of GPA and MPA patients (male vs female)
GPA MPA
Male Female Male Female
No. of patients 210 207 54 52
Age (years); median 51.0 52.6 60.7 66.1
Time to diagnosis1 (month); median, [IQR] 4.9 [2.24–12.0] 7.0 [3.0–20.4]+ 3.9 [2–9.2] 6.9 [2–12.8]
Diagnosis to 1. Relapse (month); median [IQR] 14 [7.5–31.5] 21.5 [10–30] 16 [9–45] 18.5 [13.75–39]









Number of organs involved; mean (median) [IQR] 3.37 (3) [2–4] 3.17 (3) [2–4] 2.62 (2) [2–3.75] 2.17 (2) [1–3]
Permanent renal replacement therapy n (%) 32 (15.2) 23 (11.1) 18 (33.3) 18 (34.6)
Temporary renal replacement therapy n (%) 21 (10) 11 (5.3) 4 (7.4) 7 (13.5)
Death n (%) 26 (12.4) 16 (7.7) 6 (11.1) 7 (13.5)
Patients with relapse n (%) 130 (61.9) 112 (54.1) 15 (27.7) 12 (23.1)
Relapse rate& 19.2 ± 1.2 16.8 ± 1.2 13.2 ± 2.4 10.8 ± 2.4
Organ involvement
General n (%) 180 (85.7) 175 (84.5) 39 (72.2) 44 (84.6)
Skin n (%) 74 (35.2) 66 (31.9) 12 (22.2) 12 (23.1)
Eye n (%) 46 (21.9) 68 (32.8) 2 (3.7) 2 (3.9)
ENT n (%) 150 (71.4) 165 (79.7)* 11 (20.4) 7 (13.5)
Respiratory n (%) 171 (81.4) 144 (69.6)+ 34 (62.9) 26 (50.0)
Heart n (%) 31 (14.8) 24 (11.6) 8 (14.8) 3 (5.8)
GI n (%) 21 (10.0) 25 (12.1) 8 (14.8) 4 (7.7)
Renal n (%) 149 (70.9) 103 (49.8)# 51 (94.4) 50 (96.2)
Urinary n (%) 4 (1.9) 4 (1.9) 2 (3.7) 1 (1.9)
CNS n (%) 22 (10.5) 23 (11.1) 2 (3.7) 0 (0)
Peripheral nerves n (%) 40 (19.1) 35 (16.9) 12 (22.2) 8 (15.4)
Creatinine max2 (mg/dl); median, [IQR] 1.6 [1.0–4.52] 1.0 [0.9–2.0]# 3.0 [1.85–5.37] 4.3 [2.0–6.14]
Subjects with renal involvement creatinine max (mg/dl); median,
[IQR]
2.5 [1.3–5.7] 2.0 [1–4.0]*
Subjects without renal involvement creatinine max (mg/dl);
median, [IQR]
1.0 [0.99–1] 1.0 [0.8–1]
CRP at baseline (mg/l); median, [IQR] 46 [10–115.5] 31 [8–89] 35 [19–86] 32 [10–78]
CTX (g)3; median, [IQR] 9 [5–20] 8 [5.7–14.5] 6 [2–9.25] 3.5 [1.5–7]*
Smoker/previous smoker/no/missing (n)4 20/48/69/61 5/24/114/52# 5/24/11/13 0/23/29/0+
See Table 2 for legend
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This corresponds to other recently published Polish report [21]
and, unexpectedly, to data obtained in the Japanese population
[22], but differs from the results published by French
Vasculitis Study Group and from Spain [19, 20]. As the pro-
portion of anti-MPO positive and anti-MPO negative EGPA
patients in our cohort was similar to the one observed in other
European countries [2], higher proportion of women in our
registry may represent a true difference between Central and
South-Western Europe. Ethnic and geographic differences in
epidemiology and clinical presentation of AAV have been
already described in other populations throughout the world
[8, 9], [10, 23].
At this point, it is important to note that there were impor-
tant differences within EGPA group depending on their
ANCA status. The presence of anti-MPO ANCA in EGPA
not only modified the age at disease diagnosis but also its
clinical manifestations. This is in accordance with other clin-
ical reports describing ANCA-positive EGPA patients [11,
19]. EGPA may also pose some problems with definitions.
For example, in our cohort, the highest frequency of relapses
was surprisingly observed in EGPA patients. However, it
might rather reflect asthma exacerbations than true vasculitic
relapse [24]. It is than well substantiated to analyze EGPA
patients separately from other AAV subjects [25] with
ANCA status as an important differentiating factor [26]. Of
interest, almost 3% of our GPA patients in whom differential
blood smear was available showed increased blood eosinophil
count as defined by Lanham [27].
Usually, AAVs are characterized by a multisystem involve-
ment. Accordingly, in Polish patients, the highest number of
organs involved was found in the EGPA group (median 3.84
organs), followed by GPA (3.27), and finally MPA (2.4),
which was consistent with recently published data [18].
Differences between clinical presentation and laboratory find-
ings in GPA and MPA exist, but they overlap making differ-
ential diagnosis between these two clinical entities often dif-
ficult. As it could be expected, also in POLVAS patients, 14%
of pANCA/anti-MPO positive subjects were diagnosed with
GPAwhile 5% of MPA (or EGPA) patients showed cANCA/
anti-PR3 positivity.
In recent decades, a significant progress has been made in
effective treatment of AAV, an often life-threatening multi-
organ systemic diseases. The 5-year survival rate is now esti-
mated by some authors at 94.5% [28]. Others report the 5-year
survival in GPA ranging between 73 and 83% and in MPA,
between 45 and 85% [23, 29]. Despite a significant improve-
ment in survival noted between the last decades of the twen-
tieth century as compared to recent years [28, 29], mortality in
AAV is still about three times higher than in the general pop-
ulation [28, 29]. For this reason, it seems of utmost importance
to identify factors related to the poor outcome in AAV
patients.
In POLVAS AAV patients, predictors of death identi-
fied by logistic regression analysis slightly differed de-
pending on the AAV phenotype. Independent risk factors
for death in both GPA and MPA patients included age at
diagnosis over 65 years, chronic renal replacement thera-
py, and lower respiratory tract involvement. In addition, in
MPA, skin involvement was also independently associat-
ed with mortality which might represent a more general-
ized disease. Overall, our results concur with the findings
from other AAV cohorts [9, 20, 30]. However, a word of
caution is required while comparing different reports, as
sometimes terms defining kidney disease differed, includ-
ing Bany renal involvement^ or Bincreased serum creati-
nine concentration^ [9, 20, 31]. To clarify this issue, we
performed additional analyses applying those different
definitions of renal involvement. Only PRRT and maxi-
mal creatinine concentration ever (data not shown)
remained independently associated with death in our
AAV cohort. The general term Bkidney involvement^ did
not reach statistical significance in these analyses (p =
0.064).
As PRRTwas independently associated with death in both
GPA and MPA, we further attempted to identify risk factors
associated with PRRT. Again, the factors slightly differed de-
pending on the AAV phenotype. In GPA, a number of organs
involved was positively associated with PRRT while ENT
involvement seemed to represent a protective factor. This lat-
ter finding indicates that, in fact, limited form of GPA is char-
acterized by a more benign disease course [32]. Logistic re-
gression analysis of the whole AAV group with the addition of
ANCA specificity identified the presence of c/PR3 ANCA
(for death) and of both, c/PR3 and p/MPO ANCA for PRRT.
We did not analyzed risk factors for relapse (as an outcome
measure) in our patients as we identified time from diagnosis
(the length of retrospective observation) as the main factor
associated with the first and further relapse episodes.
Analysis of outcome in GPA patients suggested that there
were more men among those patients who died, although, in
our hands, this difference was not statistically significant. Men
were more prevalent among chronically dialyzed subjects
with GPA (see Table 4.). This corroborated with a higher rate
of kidney and lower respiratory tract involvement and lower
rate of ENT involvement—all factors identified as indepen-
dently related to poor prognosis. An increase in mortality dur-
ing the first 2 years of AAV was already observed among
Swedish AAV patients [33]. Interestingly, delay from the first
symptoms of disease to diagnosis was in males shorter than in
females. Thus, it was not an unduly delayed diagnosis but
rather a truly more severe disease course from the beginning
which characterizes men with GPA. Indeed, there are some
reports suggesting that, at least in terms of kidney involve-
ment, this might be the case [34–36]. These results also raise
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the question about the most appropriate treatment regimen and
monitoring in men with GPA.
The already mentioned, higher mortality observed during
the first 2 years from AAV diagnosis in Swedish men changed
to a higher mortality in women but only after about 8 years of
observation [33]. Longer times of observation of our cohort
may be needed to confirm those findings. In POLVAS registry,
median observation time slightly exceeded 5 years in GPA and
EGPA subjects and about 2.5 years in MPA patients.
Less than 5% of patients in our cohort was recruited be-
tween 1990 and 2000. The main reasons were possibly: the
availability of ANCA tests and less well-defined entities in-
side AAVgroup. This is nicely reflected in the recent report
from French Vasculitis Study Group showing a dramatic
change in proportion of patients diagnosed with polyarteritis
nodosa and GPA in the last decades of the twentieth century as
compared with the years after 2000 [28].
Properly planned prospective clinical trials are needed to
offer definite answers to the questions raised by our data.
Summary
In summary, this is the first multicenter retrospective study of
Polish patients with AAV. Demographic characteristics and
disease manifestation of patients in POLVAS registry are sim-
ilar to those from other European countries. Following inde-
pendent risk factors related to death were identified in both
GPA and MPA: age at diagnosis > 65 years and PRRT. In
addition, risk factors for death in GPA included lower respi-
ratory tract involvement and in MPA, skin involvement. We
also identified more frequent kidney and lower respiratory
tract involvement in male patients with GPA. This observation
requires confirmation in prospective clinical trials, and maybe
a change in the therapeutic approach in male patients.
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